Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (181-190 of 241) with videos related to

Pageof 25
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibDavid A Eberhard, Bruce E Johnson, Lukas C Amler, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
A cellular and spatial atlas of <i>TP53</i> -associated tissue remodeling in lung adenocarcinomaWilliam Zhao, Benjamin Kepecs, Navin R Mahadevan, et al.
Nature Genetics|March 2, 2021
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasionChris J Frangieh, Johannes C Melms, Pratiksha I Thakore, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2005
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyRoy S Herbst, Dean F Bajorin, Harry Bleiberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Cancer|May 12, 2026
The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancerShetal A Patel, Jonathan L Heald, Michael Nead, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 TrialDaniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing ProgramBrittany L Bychkovsky, Tianyu Li, Jilliane Sotelo, et al.
Pageof 25

Showing results (181-190 of 241) with videos related to

Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibDavid A Eberhard, Bruce E Johnson, Lukas C Amler, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
A cellular and spatial atlas of <i>TP53</i> -associated tissue remodeling in lung adenocarcinomaWilliam Zhao, Benjamin Kepecs, Navin R Mahadevan, et al.
Nature Genetics|March 2, 2021
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasionChris J Frangieh, Johannes C Melms, Pratiksha I Thakore, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2005
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyRoy S Herbst, Dean F Bajorin, Harry Bleiberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Cancer|May 12, 2026
The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancerShetal A Patel, Jonathan L Heald, Michael Nead, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 TrialDaniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing ProgramBrittany L Bychkovsky, Tianyu Li, Jilliane Sotelo, et al.
Pageof 25